Payment overview · 2025
General Payments
$33,342.79
160 reported records · 16 companies
Healthcare provider profile · identity verified
Matthew Mullen, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · MOUNTAIN BRK, AL · NPI 1336439595
Verified facts
What the public records show
CMS Open Payments records show Matthew Mullen, MD received $33,342.79 in general payments during 2025 across 160 reported records.
Janssen Biotech, Inc. accounted for 90.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Kevzara, Rinvoq, Tremfya, Xeljanz.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Enbrel by this doctor in 2024.
GENZYME CORPORATION reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEVZARA as an associated drug or biological on 5840 records involving 2002 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Kevzara by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REMICADE as an associated drug or biological on 113 records involving 89 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Remicade by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TREMFYA as an associated drug or biological on 292917 records involving 40097 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Tremfya by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xeljanz by this doctor in 2024.
SOBI, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kineret as an associated drug or biological on 1818 records involving 1208 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kineret by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $30,284.38 | 90.8% | 42 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $611.99 | 1.8% | 23 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $535.52 | 1.6% | 15 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $465.79 | 1.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $314.63 | 0.9% | 17 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $284.51 | 0.8% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $258.94 | 0.8% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $174.33 | 0.5% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.47 | 0.5% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $114.99 | 0.3% | 4 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $34.21 | 0.1% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $31.35 | 0.1% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $25.28 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.13 | 0.1% | 1 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $17.33 | 0.1% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.94 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,233.00 | 7 |
| Travel and Lodging | $5,675.79 | 8 |
| Food and Beverage | $4,154.00 | 144 |
| Consulting Fee | $2,280.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $30,284.38 | 42 | 2025 |
Source payment records
|
|||||
| SIMPONI ARIA Normalized: simponi aria |
Biological | Janssen Biotech, Inc. | $19,668.52 | 18 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $535.52 | 15 | 2025 |
Source payment records
|
|||||
| KEVZARA Normalized: kevzara |
Biological | GENZYME CORPORATION | $465.79 | 9 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $428.59 | 15 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $268.55 | 16 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $258.94 | 11 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $183.40 | 8 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $174.33 | 12 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $150.47 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $130.75 | 6 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $114.99 | 4 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $109.98 | 7 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $48.91 | 2 | 2025 |
Source payment records
|
|||||
| HADLIMA Normalized: hadlima |
Drug | Organon LLC | $34.21 | 2 | 2025 |
Source payment records
|
|||||
| Gamifant Normalized: gamifant |
Drug | SOBI, INC | $31.35 | 1 | 2025 |
Source payment records
|
|||||
| TERIPARATIDE Normalized: teriparatide |
Drug | Almatica Pharma LLC | $25.28 | 1 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $23.13 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| Cimzia Normalized: cimzia |
Drug | UCB, Inc. | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $15.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEVZARA kevzara |
2025 | Kevzara | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TREMFYA tremfya |
2025 | Tremfya | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XELJANZ xeljanz |
2025 | Xeljanz | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GENZYME CORPORATION Exact reporting entity; no affiliate inference |
2025 | KEVZARA open payments reported associated product |
CMS Open Payments — General Payments 5840 supporting records · 2002 recipient NPIs · example record 1233195032 |
Kevzara · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | REMICADE open payments reported associated product |
CMS Open Payments — General Payments 113 supporting records · 89 recipient NPIs · example record 1174377572 |
Remicade · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | TREMFYA open payments reported associated product |
CMS Open Payments — General Payments 292917 supporting records · 40097 recipient NPIs · example record 1174257364 |
Tremfya · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SOBI, INC Exact reporting entity; no affiliate inference |
2025 | Kineret open payments reported associated product |
CMS Open Payments — General Payments 1818 supporting records · 1208 recipient NPIs · example record 1240223689 |
Kineret · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 446 | 152 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 425 | 164 |
| Prednisone | Prednisone | 315 | 112 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 237 | 66 |
| Tramadol Hcl | Tramadol Hcl | 165 | 45 |
| Gabapentin | Gabapentin | 153 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 146 | 59 |
| Humira(Cf) Pen | Adalimumab | 130 | 22 |
| Enbrel Sureclick | Etanercept | 104 | 19 |
| Pregabalin | Pregabalin | 90 | 18 |
| Celecoxib | Celecoxib | 89 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 87 | 17 |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 80 | suppressed |
| Allopurinol | Allopurinol | 79 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 26 |
| Colchicine | Colchicine | 61 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 29 |
| Methocarbamol | Methocarbamol | 52 | 21 |
| Rasuvo | Methotrexate/Pf | 52 | suppressed |
| Leflunomide | Leflunomide | 50 | 24 |
| Benlysta | Belimumab | 45 | suppressed |
| Orencia Clickject | Abatacept | 45 | suppressed |
| Meloxicam | Meloxicam | 43 | 21 |
| Alendronate Sodium | Alendronate Sodium | 41 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 15 |
| Methylprednisolone | Methylprednisolone | 36 | 15 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 35 | suppressed |
| Actemra | Tocilizumab | 33 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 31 | 13 |
| Azathioprine | Azathioprine | 30 | suppressed |
| Omeprazole | Omeprazole | 30 | 12 |
| Taltz Autoinjector | Ixekizumab | 28 | suppressed |
| Humira Pen | Adalimumab | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 22 | suppressed |
| Xeljanz Xr | Tofacitinib Citrate | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Mycophenolic Acid | Mycophenolate Sodium | 21 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 21 | suppressed |
| Avsola | Infliximab-Axxq | 20 | suppressed |
| Kevzara | Sarilumab | 20 | suppressed |
| Rinvoq | Upadacitinib | 20 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 19 | suppressed |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 19 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 19 | suppressed |
| Febuxostat | Febuxostat | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Tremfya | Guselkumab | 17 | suppressed |
| Cosentyx Sensoready Pen | Secukinumab | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 15 | suppressed |
| Remicade | Infliximab | 15 | suppressed |
| Kineret | Anakinra | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 12 | suppressed |
| Xeljanz | Tofacitinib Citrate | 12 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 11 | suppressed |
| Modafinil | Modafinil | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33,342.79 · 160 records | Janssen Biotech, Inc. | ACTHAR, BENLYSTA, Bimzelx, COSENTYX, Cimzia, EVENITY, Gamifant, HADLIMA, HYRIMOZ, KEVZARA, OCTAGAM IMMUNE GLOBULIN (HUMAN), ORENCIA, OTEZLA, RINVOQ, SAPHNELO, SIMPONI ARIA, SKYRIZI, TALTZ, TERIPARATIDE, TREMFYA, UPLIZNA, XELJANZ | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error